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Abstract: The primary antibody deficiency syndromes are a rare group of disorders that can 
present at any age, and for which delay in diagnosis remains common. Replacement therapy 
with immunoglobulin in primary antibody deficiencies increases life expectancy and reduces the 
frequency and severity of infection. Higher doses of immunoglobulin are associated with reduced 
frequency of infection. Late diagnosis and delayed institution of immunoglobulin replacement 
therapy results in increased morbidity with a wide variety of organ-specific   complications and 
increased mortality. Risks of immunoglobulin therapy are minimized by modern manufacturing 
processes, although patients can experience both immediate and delayed adverse reactions, and 
concerns remain over the transmission of prions in plasma. Immunoglobulin therapy leads to 
improvements in overall quality of life, and many of the improvements relate to reduced   infection 
rates and fear of future infections, strongly suggesting that the immunoglobulin therapy itself 
is the major factor in this improvement. There are limited data on the economic benefits of 
immunoglobulin therapy, with the fluctuating costs of immunoglobulins making comparison 
between different studies difficult. However, estimates suggest that early   intervention with 
immunoglobulin replacement compares favorably with prolonged therapy for other more 
  common chronic diseases.
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Introduction
The primary immunodeficiencies are a rare group of disorders in which the fundamental 
defect is an inability to maintain an effective immune response to an invading pathogen. 
They can be categorized into a number of different groups:
•	 Combined immunodeficiencies, in which defects of both cellular and humoral 
immunity result most commonly from single defects in genes encoding proteins 
critical for lymphocyte development; these disorders usually present in early child-
hood and are usually fatal without hematopoietic stem cell transplantation.
•	 Antibody deficiencies, which result from a variety of single gene defects, and most 
commonly more complex polygenic disorders, in which failure of an effective 
immunoglobulin response to infection places the individual at significant risk of 
life-threatening infection, most commonly with encapsulating bacteria, such as 
Streptococcus pneumoniae or Haemophilus influenzae.
•	 Complement deficiencies, in which a genetically defined inability to produce 
complement components places the individual at risk of a variety of infections 
and potentially inflammatory complications.
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•	 Phagocytic disorders, most notably chronic   granulomatous 
disease, usually as a result of X-linked or autosomal 
recessive inheritance; susceptibility to infection with 
catalase negative bacteria, most typically Staphylococcus 
aureus, resulting in abscesses and granuloma formation, 
is the hallmark of this group of disorders.
•	 Defects in innate immunity, at present most commonly 
those involving the Toll-like receptor pathways, where 
the lack of an effective inflammatory response both 
increases susceptibility to infection from bacterial and 
fungal pathogens and results in tissue damage as a 
  consequence of recurrent infection.
Immunoglobulin replacement therapy is most commonly 
indicated in defects of antibody production, but is often 
used in the context of severe combined immunodeficiency, 
both before and after stem cell transplant, where poor B cell 
engraftment may require long-term immunoglobulin support. 
Some defects in innate immunity, in particular the hyper IgE 
syndrome, can develop a degree of antibody deficiency which 
may require immunoglobulin replacement therapy.
The remainder of this paper discusses the history of 
immunoglobulin replacement therapy, current practices, and 
the products available, focusing on the therapeutic benefit 
and risk of treatment. The primary antibody deficiencies are 
focused upon, given that these are the most common of the 
primary immunodeficiencies, and for which immunoglobulin 
replacement therapy is most widely indicated. In addition, the 
evidence of efficacy for immunoglobulin replacement therapy 
is most clearly demonstrated in this group of disorders.
Clinical presentation
The International Union of Immunological Societies has 
developed diagnostic criteria for a wide range of primary 
immunodeficiencies, including the commoner primary 
antibody deficiencies.1 Infections with encapsulated bacteria 
such as H. influenzae and S. pneumoniae are the commonest 
presenting features,2,3 with recurrent pneumonia, sinusitis, 
otitis media, and acute bronchitis being most common 
infective histories obtained from patients presenting with 
primary antibody deficiency. Infections often respond 
to standard treatment, only to recur once therapy has 
finished. Bronchiectasis and chronic sinusitis are common 
complications before diagnosis and treatment.4 Although 
bacterial infections are the most common, patients with 
the common variable immunodeficiency spectrum of 
disorders are prone to fungal, viral, and protozoal infection, 
including opportunistic organisms, particularly when there 
is T lymphopenia or evidence of T cell dysfunction.
In addition to these infective presentations, underlying 
dysregulation of the immune system, thought to be inherent 
in common variable immunodeficiency, is illustrated by 
the observation that patients can present with systemic or 
organ-specific autoimmunity.2,3,5 This is most commonly 
hematological. Other organ-specific autoimmunity, 
eg,   pernicious anemia secondary to autoantibodies directed 
against intrinsic factor, is also common and can be the 
presenting feature of the condition.
A subgroup of patients with common variable immu-
nodeficiency can present with or develop a granuloma-
tous   syndrome affecting the liver, spleen, lungs, and 
gastrointestinal tract during the course of their disease. This 
can often appear similar to other granulomatous conditions, 
such as Crohn’s disease or sarcoidosis, and can lead to 
diagnostic confusion and delay in appropriate therapy.
History of immunoglobulin therapy
Following the report by Colonel Ogden Bruton in 1953 of what 
was subsequently identified as X-linked agammaglobulinemia6 
treated with replacement plasma, early attempts to replace 
absent immunoglobulin progressed from the use of fresh 
frozen plasma to relatively impure preparations of immuno-
globulin given intramuscularly.
The processes of cold-ethanol and pH fractionation 
to extract immunoglobulin from plasma were developed 
in the 1940s, with preparations containing 70%–80% 
monomeric IgG and substantial amounts of IgA and IgM. 
Such preparations proved useful in reducing infections in 
patients with X-linked agammaglobulinemia when given 
intramuscularly, but produced life-threatening anaphylactic 
reactions when given intravenously. Enzymatic modifications 
of IgG resulted in more monomeric preparations, but with a 
significant loss of function, including complement-binding 
activity.
Identification of processes that could result in the 
preparation of intact IgG at high purity, involving low pH and 
trace pepsin concentrations, precipitation by polyethylene 
glycol, or purification using diethyldiaminoethyl ion-
exchange chromatography, paved the way for development 
of stable products that could be administered intravenously, 
and many patients with primary antibody deficiencies were 
moved onto these newer preparations.
Modern manufacturing processes
The quality of plasma collected directly impacts on the final 
quality of the intravenous immunoglobulin or subcutaneous 
immunoglobulin preparation. Strict quality assurance 
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measures in place throughout the process ensure high levels of 
reliability and consistency. Collection centers are overseen by 
national and international regulatory authorities, and should 
comply with Good Manufacturing Practice. Plasma donors 
have a documented medical history and should be exempt 
from risk factors for plasma-borne infectious agents. Upon 
collection, most plasma for intravenous immunoglobulin is 
frozen to −25°C or −30°C within 24 hours, and kept in this 
state for several months.
Individual donations are screened for human immunodefi-
ciency virus (HIV) 1 and 2 and hepatitis C antibodies, as well 
as hepatitis B surface antigen. Many manufacturers now screen 
minipools of donations for genomic viral   markers of HIV , 
hepatitis A, B, and C, and parvovirus B19. The   manufacturing 
pool should then screen negative for the   hepatitis C virus 
nucleic acid test, HIV antibodies, and   hepatitis B surface 
antigen, often now with additional screening for hepatitis 
A RNA and parvovirus B19 DNA.
In most processes, plasma is then subjected to controlled 
thawing at 2°C–3°C, known as cryoprecipitation, with the 
cryoprecipitate removed, leaving a “cryo-poor” fraction 
containing the immunoglobulin, after removal of fibrinogen 
by ethanol precipitation at neutral pH. Subsequent processes 
may involve ion-exchange chromatography, use of caprylic 
acid, incubation at low pH, and nanofiltration to ensure the 
highest purity and maximal yield.
Previously, the end-products were produced in lyophilized 
form, but this resulted in a risk of aggregate formation upon 
reconstitution, and the discovery that IgG remains stable in 
liquid form at pH 4.25 and that patients could tolerate such 
preparations has resulted in a move to liquid preparations 
at low pH with the addition of stabilizers, such as polyols, 
sugars, and, increasingly, amino acids, such as proline or 
isoleucine.
For a number of years, intravenous immunoglobulin 
products were provided at 5% concentration, requiring a 
number of hours of infusion time and with the disadvantage 
of comparatively high total volumes. The latter issue could be 
of relevance in elderly or frail patients with cardiorespiratory 
disease or renal impairment. More recently, manufacturers 
have moved to more concentrated products for intravenous 
use, typically 10%, resulting in faster infusion times and 
smaller overall volume product.7–10
Early subcutaneous immunoglobulin products were 
developed using products originally designed for intramus-
cular use, typically at 16% concentration. More recently, 
CSL Behring has developed a 20% product (Hizentra®), for 
subcutaneous use. Again, the smaller volumes and higher 
concentration bring the potential benefits of a larger dose and 
faster infusion times. It is likely that manufacturers will move 
towards generally higher concentrations of product in order 
to improve the potential for higher dosing and more rapid 
infusion times which will improve the quality of treatment 
for patients.
Treatment protocols
Once a diagnosis has been made, this should be fully 
explained to the patient and their family. The implications 
of this lifelong diagnosis and potential complications should 
be outlined at an early stage. Therapeutic options should 
then be discussed with the patient, and appropriate   written 
information given to allow them to make an informed 
choice.
Many patients receive immunoglobulin therapy via the 
intravenous route, most commonly in the hospital or clinic 
setting but, in some countries, in the home setting after 
appropriate training. Replacement dosing has historically 
been in the range of 200–600 mg/kg body weight, given at 
an interval of 2–4 weeks. Routine cannulation is all that is 
required, and infusions generally last a few hours, depending 
on the manufacturer’s guidelines for infusion rates.
Home therapy
Patients and their carers can be trained to undertake therapy 
at home.11,12 Once patients are stabilized and can tolerate 
therapy, usually with intravenous immunoglobulin, they 
should be offered the option of home therapy. Formal 
psychological evaluations are not routinely performed, but 
discussions with the patient and carers are held after written 
information has been given before accepting a patient and 
carer onto the training program. Willingness to undertake 
the training and a stable home environment are the key 
factors to successful home therapy. Many centers in the 
UK have experience and expertise in training patients to 
self-administer intravenous immunoglobulin at home. 
Hospital-based training involves achievement of competence 
in aseptic technique, intravenous cannulation, preparation of 
the delivery system, and management of adverse reactions. 
When patients and carers are felt to be ready to undertake 
home infusions, a formal agreement is reached between the 
patient and their carer, the medical and nursing teams, and 
the general practitioner that home treatment can commence. 
The nursing team makes a home visit for the first infusion to 
confirm competence in the home setting. Many patients in 
the UK and other European countries successfully undertake 
this form of treatment.
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Training for home subcutaneous immunoglobulin therapy 
is technically much more straightforward than for intravenous 
immunoglobulin therapy. The insertion of a butterfly needle 
or equivalent using standard aseptic techniques can be readily 
shown to patients or carers for children, and the use of low-
volume, battery-operated pump devices allows infusions 
of up to 20 mL at a single site to be delivered in times of 
around one hour. There are several pump designs, including 
battery-free devices such as the Freedom 60, a clockwork 
device that also allows simultaneous infusions into a number 
of sites. Larger children and adults usually need to infuse 
at two sites either on the anterior abdomen or thigh. There 
is some evidence that a rapid push technique is acceptable 
to patients.13
The use of subcutaneous immunoglobulin offers a number 
of significant practical advantages to patients and their carers, 
and can be used for home treatment where intravenous 
immunoglobulin is not practical in the home environment. 
Most UK and many European and US centers have taken full 
advantage of this, and have active home training programs 
for children and increasingly for adults as well.
Efficacy of immunoglobulin therapy
There are large numbers of randomized controlled trials exam-
ining the effectiveness of immunoglobulin treatment, but no 
placebo-controlled trial data are available. The UK Medical 
Research Council reported 201 case histories of immuno-
deficient patients treated with low doses (0.1 g/kg/month) 
of intramuscular immunoglobulin, with a 10-year survival 
rate of 37%.14 In contrast, Cunningham-Rundles and Bodian 
in 19933 reported 248 patients with common variable 
immunodeficiencies, the vast majority of whom received 
intravenous immunoglobulin 0.4 g/kg/month throughout 
the period of observation, and these patients had a 10-year 
survival of 78%. Liu et al15 concluded from these data that 
mortality was markedly higher in those treated with low-dose 
immunoglobulin. More recent European data show a further 
increase in survival rates.16 However, factors in addition to 
increased immunoglobulin dose, such as improved diagnosis 
and management of complications, are likely to have made 
a significant contribution to the increased survival seen in 
patients treated with intravenous immunoglobulin.
Replacement immunoglobulin therapy reduces the rate 
of bacterial infection, days of antibiotic usage, days of fever, 
hospital admissions, and incidence of pneumonia.17–20 Patients 
receiving higher-dose therapy have significantly fewer total 
episodes of infections per patient, and the duration of 
infection is significantly shorter than with low-dose therapy.21 
Previous studies comparing intramuscular immunoglobulin 
at 0.08–0.1 g/kg/month with intravenous immunoglobulin 
at 0.4 g/kg/month also showed that higher doses of immu-
noglobulin reduce bacterial infection rates.22
Low levels of IgG (,6 g/L) immediately pretherapy 
(termed trough levels) are associated with moderate lung 
damage (bronchiectasis).23 Significantly higher rates of 
pneumonia (per patient-year) were found in patients with 
trough IgG levels ,5 g/L (P = 0.06).23 There was also 
an increased risk of chronic lung disease and sinusitis with 
time in patients with low IgG levels.4 Data from Roifman 
et al in 200317showed that trough IgG levels .9 g/L reduced 
validated infection rates from more than 10% to 5.6%. It has 
been shown that there is a significant correlation between 
prevention of pneumonia and trough IgG levels (P = 0.012).18 
More recently, a large multicenter study demonstrated that 
intravenous immunoglobulin therapy should be aimed at 
maintaining a trough level .4 g/L to retain a reduced inci-
dence of pneumonia post-therapy, and that patients with 
common variable immunodeficiency who have low IgA 
(,0.07 g/L), IgM, and bronchiectasis at presentation have a 
higher risk of pneumonia despite therapy.24
A crossover study comparing intravenous and subcu-
taneous immunoglobulin therapy demonstrated equivalent 
efficacy in terms of infection frequency,25 and this has been 
demonstrated more recently in further studies.26,27 However, 
dosing when changing patients from intravenous to subcu-
taneous treatment should be adjusted on an individual basis 
to achieve similar levels of IgG.28
These data support the contention that, in general, higher 
doses of immunoglobulin and higher trough levels are associ-
ated with fewer infections. However, it is important to note 
that this does not translate into ideal dosage or trough IgG 
levels for all patients, because the level at which infections 
are prevented varies widely between patients. Recent data 
suggest that clinical measurements in individual patients 
may be more important than aiming for a specific trough 
IgG level,29 although a meta-analysis concluded that pro-
gressively higher trough IgG levels (achieved by increased 
dosing) correlated with a reduced incidence of pneumonia 
during therapy.30 It is also unclear if a starting dose adjusted 
for body weight is an appropriate approach for all patients 
There was no relationship between annual dose and trough 
IgG level, regardless of infusion frequency, or adjustment for 
weight or body mass index.31 Whether or not increased doses 
are truly associated with an improved outcome has yet to be 
established. Despite this lack of clear evidence, surveys sug-
gest many clinicians use dosing to achieve appropriate trough 
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levels,32 and guidelines attempting to standardize treatment 
dosing and frequency have been produced by a number of 
different countries, often as part of demand management 
strategies.33,34
Risks of immunoglobulin therapy
The risks of immunoglobulin therapy fall into three main 
categories. Immediate reactions can occur during infusions 
which can be severe, including anaphylaxis. Patients may 
experience a clinical syndrome similar to type I hypersensi-
tivity reactions, with urticaria, angioedema, bronchospasm, 
and, potentially, cardiovascular collapse. The etiology 
of such reactions remains unclear, although there have 
been reports of IgE antibodies potentially directed against 
IgA found in the infusion product. In addition, there are 
reports of the presence of IgG antibodies directed against 
IgA, as reviewed previously,35 although the area remains 
  controversial. As noted above, manufacturers attempt to 
keep the IgA content of their products as low as possible to 
minimize this risk. Of probably greater risk is the presence 
of subacute bacterial or low-grade viral infection and the 
incidence of potentially severe side effects when the patient 
is acutely infected remains high. For this reason, clinical 
units commonly operate a policy of ensuring that the patient 
is apyrexial for a 48-hour period prior to any infusion.
Patients can also experience delayed reactions to immu-
noglobulin products, occurring several hours after infusion, 
and most commonly involving headache, backache, and occa-
sional rigors. Again, the precise etiology of these reactions 
remains unclear, although both immune complex formation 
and reactivity to components used in the manufacturing 
process which appear in the final product are thought to be 
implicated in such reactions. Some reactions may relate to 
fast infusion times. The osmotic activity of the intravenous 
immunoglobulin preparations, particularly in older products 
where carbohydrate moieties are used as stabilizers, may 
cause a degree of fluid shift into the intravascular space 
during infusion. This may be exacerbated if the patient is 
relatively dehydrated, and may contribute to headache and 
other potentially delayed side effects that are seen. It is likely 
that residual infections, particularly in patients who have end-
organ damage such as bronchiectasis or sinusitis, may well 
be important in the nature of these reactions. It is clear that 
patients tolerate different products to differing extents,36 and 
if reactions persist, the brand of intravenous immunoglobulin 
should be changed. Generally, however, there is general 
acceptance that the patient should be maintained on the same 
product if at all possible to reduce the risk of transmission 
of infection, although there is no direct evidence to support 
this practice.
Adverse reactions to subcutaneous immunoglobulin 
appear to be generally much less common. This seems more 
likely to be as a consequence of the route of administration, 
with subcutaneous therapy being delivered into a relatively 
inert space when compared with the intravenous route, 
rather than inherent differences between intravenous and 
subcutaneous products.
There is an inevitable risk from pooled donated plasma 
of the transmission of plasma-borne infectious agents. 
  Intravenous immunoglobulin produced by cold-ethanol 
fractionation has been regarded as inherently safer than those 
products prepared from cryoprecipitate fractions, such as 
factor VIII. However, transmission of hepatitis C infection 
has been reported previously, although not recently. These 
outbreaks have resulted in a high level of vigilance regarding 
donor and plasma selection, and a review of manufactur-
ing processes to assess their impact on viral reduction or 
  inactivation. Cold-ethanol fractionation and incubation at 
low pH both contribute to significant reduction in viral con-
centrations under experimental conditions, although these 
are not regarded as sufficient. Additional measures, includ-
ing pasteurization, solvent detergent treatment, caprylic acid 
treatment, and nanofiltration, have all been demonstrated 
to remove viral particles to a significant extent during the 
manufacturing process. Manufacturers currently use a mul-
tistage approach with all of the above methods, often used 
in combination.
Historically, the risk of transmission of viral infection has 
been of major concern, with previous outbreaks of hepatitis C 
infection from contaminated immunoglobulin batches being 
reported in the late 1980s. It is likely that donor screening, 
plasma quarantine, and additional viral inactivation steps 
will reduce this risk substantially. Infusion-related risks of 
adverse reaction have been reduced considerably in recent 
years, due to improved manufacturing processes (see above). 
Viral transmission has not been reported since the last out-
break of hepatitis C nearly 20 years ago.37,38
The other major long-term risk, albeit at this stage theo-
retical, is the transmission of prions in plasma. The epidemic 
of bovine spongiform encephalopathy in the UK and a small 
number of other countries in the 1990s, as well as the reported 
link between bovine spongiform encephalopathy and a novel 
form of Creutzfeld-Jacob disease lead to major concerns 
about the safety of plasma donated from individuals resident 
in those countries affected by bovine spongiform encephal-
opathy, in particular the UK. As a result of these concerns, 
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a ban was placed upon the use of UK-derived plasma for the 
manufacturer of immunoglobulin and other plasma-derived 
products. This ban remains in place and is likely to do so 
for the foreseeable future. Manufacturers’ own assessments 
indicate that significant removal of prion particles (4–5 log 
reduction) occurs during the fractionation process, filtration 
steps, and precipitation procedures, suggesting that the risk 
transmission from immunoglobulin products is likely to be 
extremely low. However, case reports of transmission of 
new variant Creutzfeld-Jacob disease by blood transfusion 
indicate that a theoretical risk remains, and it is critical that, 
during the consenting process, patients, their families and 
carers, are made fully aware of the long-term potential risk 
from treatment. Clearly, these risks must be balanced against 
the evidence of benefit from therapy, outlined below.
Consequences of delayed therapy
Data from the UK in the later 1980s and early 1990s indicated 
that patients with primary antibody deficiencies experienced 
a median diagnostic delay of 3.5 years.39,40 More recent 
data suggest that this may have declined to a median of 
one year.41 In the UK, this reduction in delay may have been 
attributable to the publication of previous reports, including 
the UK Consensus Document in 199442 and the distribution of 
national guidelines in 1995. However, the delay in diagnosis 
depends on the type of antibody deficiency, and for some 
conditions (eg, IgG subclass deficiency), the average delay 
was found to be in excess of 10 years,41 although it is now 
widely accepted that IgG subclass deficiency in isolation is 
not a disorder in which immunoglobulin replacement therapy 
is required.
Diagnostic delay results in treatment delay and morbidity 
following further infections. An episode of pneumonia 
before treatment results in a 10-fold increase in risk of 
pneumonia after therapy.19 Inadequate replacement therapy 
with immunoglobulin places the patient at greater risk of 
recurrent respiratory tract infections, chronic bronchitis, and 
rhinosinusitis.2,3 Infectious diarrhea occurs with increased 
frequency in untreated patients with both common variable 
immunodeficiency and X-linked agammaglobulinemia.43 
Central nervous system infections have been reported both 
as a presenting feature and complication of primary antibody 
deficiency, particularly prediagnosis or during suboptimal 
therapy.23 Such infectious episodes are significantly reduced 
with adequate immunoglobulin replacement therapy.
In addition to acute infection, end-organ damage can 
result from delayed diagnosis and therapy. End-stage lung 
disease with the development of respiratory insufficiency 
remained the commonest cause of morbidity in large cohort 
studies from the 1990s,2,3 although there is a lack of more 
recent data. Patients may also suffer from autoimmune 
hematological disorders. In the largest case series of common 
variable immunodeficiency reported (326 patients),44 11% 
had a history of autoimmune hematological disease.
Rheumatological complications of primary antibody 
deficiencies are primarily those due to acute or chronic 
infection that resolve on appropriate antibiotic therapy and 
are   prevented by the institution of immunoglobulin therapy.45 
Skin infections may be fungal, bacterial, or viral.46 Patients 
with primary antibody deficiencies on immunoglobulin 
therapy remain at risk of a number of organ-specific and 
systemic complications, including inflammatory bowel 
disease, neurodegeneration, and malignancy.47 Estimates of 
the overall increased risk of malignancy vary from 1.8-fold 
to 13-fold, with the risk linked to the primary antibody defi-
ciency rather than the genetic background of the individual.48 
The occurrence of these and other complications emphasizes 
the need for regular clinical review by appropriately trained 
specialists and further investigations as required.
Current availability
There are a number of plasma fractionation companies 
manufacturing both intravenous and subcutaneous products. 
Their current availability in the UK is shown in Table 1. 
A majority of manufacturers provide both intravenous 
and subcutaneous products derived from the same plasma 
donation pool, and as outlined above, the current trend is 
towards higher concentration of product, with the benefits 
of reduced volume and infusion time.
It is clear that patients with primary immunodeficien-
cies tolerate certain products more than others. This 
may partly be due to the IgA content of products and the 
presence of anti-IgA antibodies in the patient, although 
the data on this issue remain unclear and, in any event, 
Table 1A intravenous immunoglobulin products currently available 
in the UK





Privigen CSL Behring 10
Flebogamma® DiF 5% Grifols 5
Flebogamma® DiF 10% Grifols 10
Octagam® 5% Octapharma 5
Octagam® 10% Octapharma 10
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Table 1B Subcutanous immunoglobulin products currently available 
in the UK
Product Manufacturer Concentration (% v/v)
Subcuvia® Baxter 16
Subgam® BPL 16
vivaglobin® CSL Behring 16
Hizentra® CSL Behring 20
Table 2 Clinical benefits of immunoglobulin replacement therapy in primary antibody deficiency
Issue Grade of evidence
increased life expectancy 2++
Reduction in rate of bacterial infection 2++
Greater morbidity from diagnostic and treatment delay 2++
Reduction in infections with increased dose 1++
improved quality of life with replacement therapy 2++
Grade of evidence
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very 
low risk of bias
1+ Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a 
very low risk of bias
1− Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias
2++ High quality systematic reviews of case-control or cohort studies 
High quality case-control or cohort studies with a very low risk of confounding 
bias, or chance and a high probability that the relationship is causal
2+ Well conducted case-control or cohort studies with a very low risk of 
confounding bias, or chance and a moderate probability that the relationship  
is causal
2− Case-control or cohort studies with a high risk of confounding bias, or chance 
and a significant risk that the relationship is not causal
3 Nonanalytic studies, eg, case reports, case series
4 Expert opinion
Abbreviation: RCT, randomized controlled trial.
manufacturers all ensure that the IgA content of their 
products is as low as possible. However, the issue of 
variable tolerability underlies the consensus best practice 
approach of ensuring that patients have access to a range 
of products, and this is endorsed by national professional 
societies, eg, The UK Primary Immunodeficiency Network 
(UK PIN, www.ukpin.org.uk). In addition, it is desirable to 
ensure continuity of product in an individual patient unless 
a change of product is required clinically. Patients should 
not have their product changed purely on the grounds of 
cost or convenience.
Quality of life issues
There is only one study that has directly compared health-
related quality of life before and after immunoglobulin 
therapy.49 This study of 25 patients with common variable 
immunodeficiency or X-linked agammaglobulinemia used 
analysis of medical records, data registers, and question-
naires (a study-specific questionnaire in addition to the 
Sickness Impact Profile50) to assess the overall quality 
of life prior to and 18 months after initiation of subcu-
taneous   immunoglobulin therapy. After 18 months of 
  subcutaneous immunoglobulin therapy, patients reported 
significant improvements across all areas of health-related 
function to levels comparable with those of healthy 
  individuals. In   addition, the patient group reported reduced 
fear of infections and decreased anxiety about their future 
health. It is reasonable to conclude that initiation of immu-
noglobulin therapy was a major factor in the improvements 
seen, although other factors relating to diagnosis and 
support from health professionals are likely to have been 
  contributory. Other studies support the overall concept that 
patients prefer home-based therapy and report improved 
quality of life when transferring from hospital-based intra-
venous immunoglobulin therapy.27,51
Other studies have assessed the quality of life of indi-
viduals already receiving immunoglobulin replacement 
therapy.52 Eighty-three percent of a cohort of adult patients 
with X-linked agammaglobulinemia rated their health as 
good, very good, or excellent. The responses indicated that 
the adult males with X-linked agammaglobulinemia had 
quality of life equivalent to that of the general male popula-
tion, other than in their perception of their own health. In this 
study, patients with X-linked agammaglobulinemia had a 
better quality of life in every parameter when compared with 
individuals with diabetes. Although direct comparison is 
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not possible, more historical data on patients with X-linked 
agammaglobulinemia indicate significant morbidity and 
poor survival rates in adult life, particularly from the era 
before intravenous immunoglobulin,53 indicating that earlier 
diagnosis and prompt initiation of adequate immunoglobulin 
replacement therapy improves overall quality of life. This is 
supported by recent data from Iran.54
In contrast, a study comparing patients with common 
variable immunodeficiency receiving intravenous immuno-
globulin with patients suffering from diabetes mellitus or 
congestive cardiac failure found that patients with common 
variable immunodeficiency had significantly worse health-
related quality of life than patients with either of the other 
conditions, unrelated to socioeconomics or disease-specific 
factors.55 However, this does not indicate that initiation of 
immunoglobulin replacement therapy fails to improve overall 
life quality.
In general, studies looking at quality of life issues 
in primary antibody deficiencies suggest that replace-
ment therapy with immunoglobulin given either by the 
intravenous or subcutaneous route is a contributory 
factor in improvement of quality of life. There are no 
studies assessing how diagnostic or treatment delay affects 
this, although pretreatment data provide some indication 
as to the overall poor quality of life suffered by   individuals 
with either undiagnosed or untreated primary antibody 
deficiencies. It could be inferred that because an increased 
dose reduces the overall infection burden, that this would 
improve quality of life further, but this has not been dem-
onstrated directly.
Economic benefits of diagnosis  
and appropriate therapy
There are a small number of studies assessing the 
cost-effectiveness of immunoglobulin therapy, but none 
  comparing no therapy with replacement therapy. All   studies 
are limited by the costs of immunoglobulin at the time of 
the study.   However, an early study compared the   potential 
cost-effectiveness of changing from intramuscular to 
  intravenous immunoglobulin.56 Because intramuscular 
  immunoglobulin therapy has often been used as a surrogate 
marker for no effective therapy, this study represents an 
attempt to compare therapy with no therapy. Twenty-three 
children with a variety of primary antibody deficiency 
states were assessed in the 2 years prior to and in the 
3 years   following the change from intramuscular immuno-
globulin to   intravenous   immunoglobulin. In particular, the 
number of days with antibiotics, number of absences from 
school,   number of days in bed or hospital, and the number 
of days with infection or fever were assessed at 3-weekly 
  intervals. The change from   intramuscular immunoglobulin 
to intravenous   immunoglobulin produced a 90% fall in the 
number of   hospital bed days. Based on 1990 Italian costs, 
the relative costs of antibiotic therapy, hospitalization, and 
immunoglobulin drug costs per month for a 20 kg child 
were 953,000 Lira for intramuscular immunoglobulin 
and 826,000 Lira for intravenous   immunoglobulin. Given 
that the quoted figures for drug costs were 160,000 Lira 
for intramuscular immunoglobulin and 468,000 Lira for 
intravenous immunoglobulin, this illustrates the significant 
overall cost-saving of adequate therapy using intravenous 
immunoglobulin.
Other studies have compared the estimated relative 
overall treatment costs of intravenous immunoglobulin 
with those of subcutaneous immunoglobulin. Such studies 
are limited by the relative drug costs, which in the case 
of the study by Gardulf et al in 199557 were based on an 
approximate cost of $14,000 per annum for intravenous 
immunoglobulin against $4650 for subcutaneous immu-
noglobulin. Perhaps not surprisingly, this study reported 
a lower overall cost for home subcutaneous immuno-
globulin therapy compared with hospital-based intravenous 
immunoglobulin therapy. A more recent study58 compared 
the costs with the German health insurance system of 
providing intravenous immunoglobulin or subcutaneous 
immunoglobulin from 18 centers in Germany. Costs were 
taken from the standard tariffs for drugs and health services 
in the German health care system in 2003. The costs consid-
ered were for the immunoglobulin products, the materials 
required for infusion, medical treatments, and sick leave 
(for caregivers of children). For adults, the overall costs per 
annum were 31,027 Euro for intravenous immunoglobulin 
and 14,893 Euro for subcutaneous   immunoglobulin. Within 
these costs, the drug costs were 30,456 Euro and 13,874 
Euro, respectively. Considering that these data are derived 
from a unit cost of 86.40 Euro for intravenous immuno-
globulin and 38.54 Euro for   subcutaneous immunoglobulin, 
at price equivalence there is effectively no cost difference 
between the two therapy routes. Smaller but similar costs 
applied to children in the study.
As part of a cost-effectiveness review of   immunoglobulin 
therapy, Hyde et al developed a Markov model to assess the 
cost-effectiveness of immunoglobulin therapy. This used 
derived mortality data based on survival estimates for 
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current immunoglobulin replacement regimes (mainly 
intravenous immunoglobulin) compared with historical 
data (mainly intramuscular immunoglobulin), although 
the authors   acknowledged that such a comparison was 
  difficult due to the lack of placebo-controlled random-
ized trial data.15   Nevertheless, a conversion of the costs 
used by Hogy et al58 into UK costs resulted in estimated 
costs per annum of £18,600 for hospital-based intravenous 
immunoglobulin therapy and £11,580 for home-based 
intravenous   immunoglobulin therapy. Costs of subcutaneous 
immunoglobulin therapy (exclusively based at home) were 
£11,760, reflecting the similar unit costs of subcutaneous 
immunoglobulin and intravenous immunoglobulin in the UK. 
Taking these data assumptions into account, the economic 
model predicted a base-case incremental cost-effectiveness 
ratio per quality-adjusted life-year of approximately £30,000. 
The incremental cost-effectiveness ratio for immunoglobulin 
therapy in primary immunodeficiency compares favorably 
with the use of prophylactic therapy in hemophilia.59
Conclusion
Immunoglobulin replacement therapy has been used for over 
50 years in the treatment of primary immunodeficiencies, 
with advances in manufacturing processes allowing safe and 
efficient delivery of intravenous immunoglobulin for the past 
30 years. This has transformed the management of patients 
with primary antibody deficiencies, resulting in prolonged 
survival, reduced morbidity, and improved quality of life 
(Table 2). The development of home therapy programs with 
both intravenous and subcutaneous immunoglobulin has 
led to further improvements in quality of life for this patient 
group, and may compare favorably with hospital-based treat-
ment programs in terms of cost-effectiveness. There is clear 
evidence that delayed initiation of immunoglobulin replace-
ment therapy results in increased morbidity and mortality, 
and improvements in overall survival seen more recently 
are most likely to relate to the earlier recognition, referral, 
and treatment of patients. Risks of immunoglobulin therapy 
relate to the potential for plasma-borne infections, although 
modern manufacturing processes have reduced this to a 
highly acceptable level. Risks of prion transmission remain 
a concern although, as yet, there is no direct evidence that 
this can occur. Adverse reactions to immunoglobulin are often 
predictable, and can be effectively managed by patient educa-
tion and appropriate planning. Available evidence indicates 
that immunoglobulin replacement therapy is cost-effective 
within current assessments of health care delivery.
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